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Abstract:  
Purpose: The feasibility and reproducibility of a new ultrasonic method for the 
direct assessment of maximal varicose vein diameter (VVD) was evaluated. A study 
was also performed to demonstrate the capacity of the method to detect changes in 
venous diameter induced by a pharmacological treatment.  
Subjects and Methods: Patients with varicose vein disease were recruited. A 
method that allows the precise positioning of patient and transducer and to perform 
scans in a gel-bath was developed. Maximal VVD was recorded both in the 
standing and supine positions. The intra-assay reproducibility was determined by 
replicate scans made within 15 minutes in both positions. The inter-observer 
variability was assessed by comparing VVDs measured during the first phase 
baseline examination with those obtained during baseline examinations in the 
second phase of the study.  
Results: The error in reproducibility of VVD determinations was 5.3%, when 
diameters were evaluated in the standing position and 6.4%, when assessed in the 
supine position. The intra-method agreement was high, with a bias between 
readings of 0.06±0.18 mm and of -0.02±0.19 mm, respectively, in standing and 
supine positions. Correlation coefficients were better than 0.99 in both positions. 
The method appears to be sensitive enough to detect small changes in VVDs 
induced by treatments.  
Conclusions: The proposed technique provides a tool of potential valid use in the 
detection and in vivo monitoring of VVD changes in patients with varicose vein 
disease. The method offers an innovative approach to obtain a quantitative 
assessment of varicose vein progression and of treatment effects, thus providing a 
basis for epidemiological surveys. 
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Introduction 
Human venous disease of the lower extremities is a condition affecting millions of 
people in the world. Its manifestations may be associated with more serious 
underlying problems undetectable by visual inspection. Apart from the cosmetic 
nuisance, varicose vein disease results in a number of uncomfortable symptoms 
which may progress, if untreated, to cutaneous pigmentation, dermatitis, 
ulcerations, haemorrhages, or superficial thrombophlebitis.[Johnson 97] Although 
uncomplicated cases of the disease are more common, venous disease should not 
be taken lightly. Steps to retard disease expression and progression should be 
implemented whenever possible. In addition, the high incidence of acute and 
chronic disease of the venous system[Johnson 97, Muller-Lisse 98] requires the application 
of reliable, non invasive, low-cost methods both for diagnosis and follow-up after 
therapy.  
Until now, goals of non–invasive vascular diagnosis of the venous system of the 
lower limbs were: 1) to evaluate the venous system during deambulation at 
baseline, after surgery or after using elastic stockings,[vettorello 94] 2) to get detailed 
information on the localization of valvular dysfunctions as the basis of any reflux 
pathology[Thibault 92, evans 99]  and, 3) to identify and quantify venous flux and reflux 
during walking.[Vettorello 1994] Although clinically important, these parameters allow 
only the assessment of gross changes due to the disease such as, i.e., the 
appearance of a new reflux due to valvular dysfunction, and do not allow the 
assessment of minor venous changes that do not affect venous flux and reflux. 
In recent years, a number of new technologies have been made available for the 
non-invasive monitoring of the evolution of varicose veins disease.[Muller-Lisse 98; 
Ghiringhelli L 92] Among these, a new technique evaluating varicose vein diameter (VVD) 
Baldassarre D.  
 
5 
may prove useful to easily follow even the minor evolution of the venous disease. 
However, difficulty in performing diameter measurements with a high degree of 
accuracy and reproducibility have so far prevented general use of these techniques 
in the clinic and in angiology research. The major factor that influences 
reproducibility of VVD evaluation is the repeated identification of the same venous 
ectasy in successive determinations. In the present study, the accuracy and 
reproducibility of a new method for VVD assessment was evaluated and quantified.  
Essaven gel (EG) is a naturally derived herbal compound indicated for the local 
treatment of venous microcirculatory alterations of the limb such as varicose veins 
and chronic venous insufficiency (CVI).[Belcaro 2001] Active ingredients of EG are 
sodium heparin, aescinate and essential phospholipids. Since there are studies 
showing that EG can cause an improvement in venous tone[Annoni 79] and in venous 
disease,[Grossmann 1991] a double blind crossover placebo controlled study was also 
carried out in order to evaluate the value of the proposed treatment on VVD 
changes in a group of patients with varicose vein disease.  
 
Patients and methods 
36 patients (11 males and 25 females; age from 31 to 67 years) with a diagnosis of 
varicose vein disease entered the study. A written informed consent was obtained 
from all subjects and the study was approved by the Institutional Review Board. 
The subjects were recruited with the unique criteria that they had a measurable 
VVD.  
Measurements were made in a temperature controlled room at 24±2°C, after 15 
minutes of acclimatization. 
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Exclusion criteria were: a) incompetence of deep venous circles of lower extremities 
as determined by the Perthes’ test,[kim 00] b) no administration of systemic or local 
drugs with trophic action (i.e. anti-edematous or analgesic agents) during the 30 
days preceding the study, c) known hypersensitivity to EG, d) presence of other 
pathologies, especially of the skin, that could interfere with drug application or with 
the evaluation of treatment, e) poor treatment compliance. 
At each visit the subjects’ VVD was assessed in the standing and supine positions. 
In order to assess the intra- and inter-assay reproducibility, all the examinations 
were performed by the same sonographer (D.B) and followed exactly the same 
scan protocol. Three patients performed the baseline assessment but did not 
complete the trial for reasons not connected to the study. These patients were 
considered for the intra-assay reproducibility studies but their data were not 
included in the pharmacological study. The remaining 33 patients completed the 
trial without any serious adverse events; they remained clinically stable during the 
study, and did not change any concomitant drug therapy. Compliance in these 33 
patients was 100% as assessed by counting of tubes returned.  
 
An ESAOTE AU4 ultrasonograph, configured with a 10-13 MHz linear array probe 
which maintains an axial resolution of about 0.2 mm was used to image VVDs. This 
type of ultrasonic transducer focalizes images in a range of depth from 2.5 to 3 cm. 
Thus, if used as such, it does not allow to image very superficial vessels such as 
subcutaneous veins. In order to solve this problem the probe was assembled with 
an appropriate spacer (figure 1), which allows to separate the probe from the skin 
by 2-2.5 cm, interposing a pipe of rubber filled with water. In addition, since veins 
may easily collapse changing their diameter even with a very light skin 
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compression, the ultrasonic scans were performed in a gel-bath, carefully avoiding 
any contact between the spacer and the patient’s skin (figure 1, right panel and 
figure 2, bottom panels). This spacer was appropriately modified with two plastic 
rings, thus imposing a fixed distance between the spacer and the skin (figure 1). 
The subcutaneous varicose veins’ anatomy is composed of a series of messy and 
not easily recognizable ectasies (figure 3, right panel). Thus, in order to improve 
accuracy and reproducibility of measurements of the diameters of ectasies, a 
specific equipment which allows to identify, at each visit, exactly the same ectasy 
measured in the first examination was developed (figure 2, top panels). This new 
methodology consists of a series of external reference guides allowing the precise 
positioning of patient and transducer as in the previous examination. Specifically, 
the equipment consists of a small platform adjustable in height with a precision of 1 
mm (figure 2, left panels). This platform is used to support the probe which, in turn, 
was assembled with the spacer. The platform allows to study the patient in the 
standing position, also allowing a circumferential scan of the area of interest, thus 
accurately avoiding unintentional vertical movements of the transducer. The 
platform also allows to draw a horizontal line on the patient’s skin necessary for the 
positioning of a second vertical platform for precise probe positioning on the leg 
when the patient is in the supine position (figure 2, right panels). 
During the first scanning, the position of the feet with respect to the platform is 
recorded by tracing feet perimeters on an individual paper sheet (figure 2, top and 
left panel). The height of the horizontal platform is adjusted according to the 
position of the ectasy and then recorded. The probe is positioned on the platform 
and approached to the skin, carefully avoiding any compression. When a selected 
ectasy is imaged, the probe position on the platform is designated by specific 
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coordinates. In addition, images of the ectasies chosen for diameter measurements 
are printed for comparison with images obtained in the following visits (example in 
figure 3, right panel). Traced footprints, height of the platform and probe position as 
well as printed images guided the operator in the search for the same ectasy during 
the following scans. When measurements in the standing position are completed 
the patient takes the supine position. The horizontal line drawn on the skin during 
the standing examination is used for positioning of the vertical platform for the 
supine examination (figure 2, right panels). Once positioned, the vertical platform 
helps the operator in the search of the same ectasy visualized in the standing 
position. Also these images, visualized for venous diameter measurements in the 
supine position, are printed and stored for visual comparison with images obtained 
at the following visits.  
After 15 minutes of rest, in the sitting position, measurements of ectasies in the 
standing and supine position are repeated for the assessment of intra-assay 
reproducibility. The complete procedure is generally carried out in less than 40 
minutes. 
In order to obtain a higher accuracy, the VVD of each imaged ectasy was obtained 
by averaging values of at least three randomly chosen frames. The individual 
subject's mean VVD values were then calculated averaging values from all 
visualized ecstasies. 
 
Essaven gel administration 
In order to assess the method capacity to detect VVD changes induced by a 
pharmacological treatment, a double-blind, crossover study, was performed. To this 
aim, after the baseline visit, patients with varicose vein disease were randomly 
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allocated either to therapy with Essaven Gel (EG) (AVENTIS PHARMA S.p.A. Italy) 
or to placebo. After a treatment period of 4 weeks, each patient was switched to the 
respective alternate treatment option for another 4 weeks. EG was administered 3 
times daily in a thin film, evenly distributed over the area of interest. Patients were 
instructed to standardize gel applications as follows: a cylinder of 3 cm of gel (about 
0.6 g of compound) was carefully measured in length and applied to the area of 
interest. A superficial standard massage was made using two fingers for 5 minutes 
in circulatory motions stimulating absorption. After the baseline investigation, 
patients were monitored again after one month of treatment. Treatment was 
repeated with a cross-over design after a wash-out period of two weeks. The 
operator was unaware of the contents of the gel tube. Sealed envelopes were 
opened at the end of the evaluation of all subjects and data entry. The 
randomization process was controlled by an external Clinical Research 
Organisation. 
 
Intra- and inter-assay variability 
Intra- and inter-assay repeatability in VVD determination have been investigated. In 
order to estimate intra-assay variability, subjects underwent the ultrasonic VVD 
examination twice, 15 minutes apart. For the analysis, data of replicate scans 
performed in the two baseline visits of the cross-over study have been pooled and a 
total of 72 replicate scans analyzed. 
Inter-assay variability was evaluated by comparing VVD values obtained averaging 
measurements of the two replicate scans obtained during the baseline examination 
of the first phase with those obtained during the second baseline examination of the 
crossover phase performed after 15 days of wash out. Thus a total of 36 duplicate 
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values were analyzed. Measurements and calculations of the average diameter of 
all ectasies considered were carried out, on line, by an independent blind 
investigator.  
 
Statistical analyses 
Means and SD values were used as descriptive measures of normally distributed 
variables. Error bars on the figures represent ± SD. The intra- and inter-assay 
comparisons were evaluated by estimating the consistent bias between 
measurements, as recommended by Bland and Altman.[Bland and Altman Lancet. 1986] The 
coefficient of repeatability was calculated according to the British Standards 
Institution,[British standards institution 1979] and corresponds to 2SD of the relative difference 
between replicate measurements. The response to EG administration was analyzed 
by ANOVA for repeated-measures. The crossover treatment trial was analyzed 
according to the recommendations of Hills and Armitage[Hills Br J Clin Pharmacol. 1979] for 
crossover trials.  
 
Results 
Intra-assay repeatability of VVD measurements: initial vs 15 minutes replicate 
values 
The intra-assay comparison of VVD values between the initial and replicate scan is 
shown in figure 4. Relative differences in VVD values remained constant as the 
VVD increased from 1.4 mm to 7.8 mm in the standing position (figure 4, left panel) 
and from 0.8 mm to 6.8 mm in the supine position (figure 4, right panel). Although 
there was some variability in the measurements of VVD, the intra-assay agreement 
was high, with a bias between measurements of 0.06±0.18 mm, with limits of 
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agreement ranging from -0.29 to 0.41 mm in the standing position and of -
0.02±0.19 mm and limits of agreement ranging from -0.39 to 0.36 mm in the supine 
position. The intra-assay mean absolute difference was 0.14±0.11 mm (range: 0.00 
to 0.57 mm), with a correlation coefficient of 0.99 (p<0.0001; figure 5, left panel), 
the coefficient of repeatability being 0.37 mm in the standing position. In the supine 
position the mean absolute difference was 0.14±0.12 mm (range: 0.00 to 0.51 mm), 
with a correlation coefficient of 0.99 (p<0.0001; figure 5, right panel) and a 
coefficient of repeatability of 0.37 mm. 
 
Inter-assay repeatability of VVD measurements: comparison between 
baseline values of the two phases of the pharmacological study 
The inter-assay comparison of VVD values between the baseline of the first and the 
second phase of the clinical study are shown in figure 6. As in the intra-assay 
comparison, relative differences in VVDs remained constant as the diameters of 
ectasies increased from the lowest to the highest diameter. Although also in this 
case there was some variability in VVD measurements, the inter-method agreement 
was similar to that observed in the intra-assay assessment, with a bias between 
measurements of 0.06±0.34 mm, with limits of agreement ranging from -0.61 to 
0.73 mm in the standing position (Figure 6, left panel) and of 0.07±0.40 mm, with 
limits of agreement ranging from -0.72 to 0.86 mm in the supine position (Figure 6, 
right panel). The inter-assay mean absolute difference was 0.21±0.26 mm (range: 
0.00 to 1.29 mm), the correlation coefficient 0.98 (p<0.001; figure 7, left panel) and 
the coefficient of repeatability 0.67 mm in the standing position. In the supine 
position the mean absolute difference was 0.26±0.30 mm (range: 0.01 to 1.13 mm), 
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the correlation coefficient 0.97 (p<0.0001; figure 7, right panel) and the coefficient 
of repeatability 0.37 mm. 
 
Evaluation of the method ability in detecting VVD changes induced by EG 
treatment 
No significant differences were found in any baseline clinical characteristic between 
patients allocated either to EG first (n=18) or to placebo first (n=18); (data not 
shown).  
No statistically significant EG variations on standing or supine VVD were observed 
either in the first phase or in the second cross-over phase of the study. Since one of 
the methodological errors that often occurs in this type of studies is the recruitment 
of patients not strictly comparable for the degree of venous dilatation(Cornu-Thenard 
Phlebologie 1992) analyses was repeated in more comparable patients obtained by the 
exclusion of the patients in the lowest tertile of baseline VVD.  
Changes in VVDs before and after treatment obtained in these more homogeneous 
(and probably more treatment sensitive) patients are reported in figure 8. Although 
again not statistically significant, treatment with EG induced, on average, a 
reduction in standing VVD in both phases of the cross-over study; while the placebo 
did not. Indeed, while in the placebo group mean increases in VVD of about 0.01 
mm were observed both in the first and in the second phase of the cross-over 
study, a reduction of VVD of about 0.03 mm in the first phase and of 0.09 mm in the 
second phase was observed in patients treated with EG. VVDs in the supine 
position and supine/standing VVD ratios were again unaffected by EG treatment.  
 
Discussion 
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This study demonstrates an accurate and precise method for the imaging of veins 
and venous ectasies in patients with varicose vein disease. The high tortuosity of 
varicose veins, the lack of clear points of reference, and the high collapsibility of 
subcutaneous vessels when the probe is positioned on the skin, makes standard 
ultrasound methods poorly reproducible and not applicable for the study of varicose 
vein disease in clinical research. We succeeded in bypassing the above mentioned 
problems and benefited from the specific tools described in this study. To the best 
of our knowledge this is the first study evaluating the reproducibility of VVD 
measurements and, as such, comparison of results with those found by others was 
difficult.[cornu-Thenard 92, Jeanneret 99, ] 
On the basis of our experience, variability of VVD measurements is mainly 
determined by sonographer’s subjectivity in image collection and by biological 
differences between subjects (in patients with highly tortuous ectasies, 
measurements may be less accurate). Since biological differences between 
subjects cannot be influenced, it is important to reduce, whenever possible, the 
effect of other factors determining variability.  
In the present study a) combining the probe with an appropriate spacer which 
allows to image very superficial vessels b) performing scans carefully avoiding any 
contact between the spacer and the patient’s skin, and c) using specific equipment 
for guiding the operator in patient and probe positioning, we were able to avert 
biases easily occurring upon repeated measurements. 
The ability of the proposed method to assess VVD changes is supported by its 
capacity to detect very small changes induced by EG treatment. Data in figure 8, 
indeed, make it clearly evident, that the method is sensitive enough to detect, at 
least in the standing position, VVD changes induced by this pharmacological 
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treatment.[Sirtori 2001] Standing VVDs were, in fact, consistently lower after treatment 
than at baseline, even if differences did not reach statistical significance. Because 
of the lack of statistical significance, likely due to small sample size, this finding 
must be viewed with caution; however, the fact that the effects on standing VVD 
were evident in both phases of the cross-over suggests a low probability that results 
may have been obtained only by chance.  
In conclusion, our results show the possibility of measuring VVD with high accuracy 
and precision, thus allowing to propose this method, as a reliable technique for VVD 
assessment in clinical trials and/or as suitable for short and long-term follow-up of 
patients with varicose vein disease. Such a systematic follow-up will identify 
possible associations between early alterations and the subsequent development of 
clinical conditions. Finally, changes in vein diameters induced by pharmacological 
treatments could be accurately monitored by this technology. 
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Legends to figures 
Figure 1. In the left panel is represented the spacer’s transducer which allow to 
outdistance the probe from the skin of 2-2.5 cm interposing a pipe of 
rubber filled with water. The spacer is also assembled with the two rings 
allowing ultrasonic scans in a gel-bath without contact between the 
spacer and the patient’s skin. In the right panel the spacer is assembled 
with the transducer.  
Figure 2. External reference guide which allows to identify, at each visit, exactly 
the same ectasy measured during the first examination (see text). The 
platform also permits to draw an horizontal line on the patient’s skin 
necessary for the positioning of a vertical platform (right panels) which 
allow the precise probe positioning on the leg when the patient is in 
supine position. 
Figure 3. Typical image of a subcutaneous saphenous veins of a control subject 
(left panel) and of saphenous veins ectasies (right panel) as assessed by 
B-mode ultrasonography. 
Figure 4. Intra-assay repeatability of varicose veins diameter (VVD) determination 
in the standing position (left panel) and the supine position (right panel). 
Scatterplots show the differences between the first and second scanning 
of the VVD measurements plotted against their mean. The mean 
difference (dashed line) and the limits of agreement (continuous line) are 
also indicated. 
Figure 5. Intra-assay relationship between scan 1 and scan 2 for VVD 
measurements obtained in the standing (left panel) or in the supine 
position (right panel). 
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Figure 6. Inter-assay repeatability of varicose veins diameter (VVD) determination 
in the standing position (left panel) and the supine position (right panel). 
Figure 7. Inter-assay relationship between scan 1 and scan 2 for VVD 
measurements obtained in the standing (left panel) or in the supine 
position (right panel). 
Figure 8.  VVD changes induced by Essaven gel in a cross over design after 
exclusion of patients in the first tertile of baseline VVD. Although not 
statistically significant, in both phases of the cross-over study the 
treatment seems to reduce the standing VVD in the Essaven gel treated 
group but not in the placebo treated group.  
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